Total Funding
42
36
Total FundingPost-IPO Equity raised
Growth Score
-1 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
60228
89bio is a biopharmaceutical company that develops clinical-stage therapies for liver and cardiometabolic diseases.
- Ryan Martins: Chief Financial OfficerPast Role: Revolution Medicines, CFO
- Hank Mansbach: Chief Medical Officer
Roche
About the Company
89bio is a biopharmaceutical company that develops clinical-stage therapies. The company focuses on creating medicines for patients with liver and cardiometabolic diseases. Its research uses knowledge of FGF21 as a metabolic regulator to develop therapies.
